Abstract
Advanced retinoblastoma has a reported 95% mortality rate, usually within six months of disseminated disease. Analysis of 146 consecutive retinoblastoma patients from 1983-1989 revealed 58 (39.7% with extraocular disease. Of these, 26 (44.9% manifested frank orbital tumor. The ages of this select group ranged from three months to 9.6 years, with a mean of 2.7 years. A delay in presentation appeared to be a major factor in the orbital tumors. Treatment included a combination of external beam radiation therapy delivered in divided doses (250 rads three times weekly for four weeks) and systemic intravenous chemotherapy (consisting of Vincristine, Cytoxan, and Adriamycin) administered monthly over a one-year period. Out of 42 children who had at least one year follow-up after treatment, IS (36% were still surviving. Two years after completion of treatment, however, the survival statistics decreased to 13.8% (8/58) for all patients. This total includes a subset of 12/58 patients receiving palliative radiotherapy for advanced neoplasms, carrying 100% mortality. The overall data indicates that aggressive multimodality therapy can, in part, arrest progression of extraocular disease and thereby prevent the high attrition rate associated with metastatic disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 19-26 |
| Number of pages | 8 |
| Journal | Orbit |
| Volume | 12 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1993 |
| Externally published | Yes |
Fingerprint
Keywords
- Extraocular neoplasm
- Malignant ocular tumor
- Orbital invasion
- Retinoblastoma
ASJC Scopus subject areas
- Ophthalmology
Cite this
Extraocular retinoblastoma in Saudi arabia. / Senft, Susan H.; Johnson, Thomas; Nasr, Amin M.
In: Orbit, Vol. 12, No. 1, 1993, p. 19-26.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Extraocular retinoblastoma in Saudi arabia
AU - Senft, Susan H.
AU - Johnson, Thomas
AU - Nasr, Amin M.
PY - 1993
Y1 - 1993
N2 - Advanced retinoblastoma has a reported 95% mortality rate, usually within six months of disseminated disease. Analysis of 146 consecutive retinoblastoma patients from 1983-1989 revealed 58 (39.7% with extraocular disease. Of these, 26 (44.9% manifested frank orbital tumor. The ages of this select group ranged from three months to 9.6 years, with a mean of 2.7 years. A delay in presentation appeared to be a major factor in the orbital tumors. Treatment included a combination of external beam radiation therapy delivered in divided doses (250 rads three times weekly for four weeks) and systemic intravenous chemotherapy (consisting of Vincristine, Cytoxan, and Adriamycin) administered monthly over a one-year period. Out of 42 children who had at least one year follow-up after treatment, IS (36% were still surviving. Two years after completion of treatment, however, the survival statistics decreased to 13.8% (8/58) for all patients. This total includes a subset of 12/58 patients receiving palliative radiotherapy for advanced neoplasms, carrying 100% mortality. The overall data indicates that aggressive multimodality therapy can, in part, arrest progression of extraocular disease and thereby prevent the high attrition rate associated with metastatic disease.
AB - Advanced retinoblastoma has a reported 95% mortality rate, usually within six months of disseminated disease. Analysis of 146 consecutive retinoblastoma patients from 1983-1989 revealed 58 (39.7% with extraocular disease. Of these, 26 (44.9% manifested frank orbital tumor. The ages of this select group ranged from three months to 9.6 years, with a mean of 2.7 years. A delay in presentation appeared to be a major factor in the orbital tumors. Treatment included a combination of external beam radiation therapy delivered in divided doses (250 rads three times weekly for four weeks) and systemic intravenous chemotherapy (consisting of Vincristine, Cytoxan, and Adriamycin) administered monthly over a one-year period. Out of 42 children who had at least one year follow-up after treatment, IS (36% were still surviving. Two years after completion of treatment, however, the survival statistics decreased to 13.8% (8/58) for all patients. This total includes a subset of 12/58 patients receiving palliative radiotherapy for advanced neoplasms, carrying 100% mortality. The overall data indicates that aggressive multimodality therapy can, in part, arrest progression of extraocular disease and thereby prevent the high attrition rate associated with metastatic disease.
KW - Extraocular neoplasm
KW - Malignant ocular tumor
KW - Orbital invasion
KW - Retinoblastoma
UR - http://www.scopus.com/inward/record.url?scp=0027238428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027238428&partnerID=8YFLogxK
U2 - 10.3109/01676839309029879
DO - 10.3109/01676839309029879
M3 - Article
VL - 12
SP - 19
EP - 26
JO - Orbit
JF - Orbit
SN - 0167-6830
IS - 1
ER -